Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Parkinson's Disease

  Free Subscription


06.03.2017

1 Brain Res
3 J Neural Transm (Vienna)
1 J Neurochem
2 J Neurol Neurosurg Psychiatry
3 Mov Disord
1 Nervenarzt
2 Neurochem Res
1 Neurol Clin Pract
5 Neurology
1 Neurosci Lett
4 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Brain Res

  1. BALUCHNEJADMOJARAD T, Rabiee N, Zabihnejad S, Roghani M, et al
    Ellagic acid exerts protective effect in intrastriatal 6-hydroxydopamine rat model of Parkinson's disease: Possible involvement of ERbeta/Nrf2/HO-1 signaling.
    Brain Res. 2017 Feb 23. pii: S0006-8993(17)30092.
    PubMed     Text format     Abstract available


    J Neural Transm (Vienna)

  2. MULLER T, Ohm G, Eilert K, Mohr K, et al
    Benefit on motor and non-motor behavior in a specialized unit for Parkinson's disease.
    J Neural Transm (Vienna). 2017 Feb 28. doi: 10.1007/s00702-017-1701.
    PubMed     Text format     Abstract available

  3. GARN H, Coronel C, Waser M, Caravias G, et al
    Differential diagnosis between patients with probable Alzheimer's disease, Parkinson's disease dementia, or dementia with Lewy bodies and frontotemporal dementia, behavioral variant, using quantitative electroencephalographic features.
    J Neural Transm (Vienna). 2017 Feb 27. doi: 10.1007/s00702-017-1699.
    PubMed     Text format     Abstract available

  4. HOGLINGER GU, Kassubek J, Csoti I, Ehret R, et al
    Differentiation of atypical Parkinson syndromes.
    J Neural Transm (Vienna). 2017 Feb 27. doi: 10.1007/s00702-017-1700.
    PubMed     Text format     Abstract available


    J Neurochem

  5. ANDERSEN AD, Blaabjerg M, Binzer M, Kamal A, et al
    Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: Effect of L-DOPA treatment and changes in levodopa-induced dyskinesia.
    J Neurochem. 2017 Feb 28. doi: 10.1111/jnc.13997.
    PubMed     Text format     Abstract available


    J Neurol Neurosurg Psychiatry

  6. HO AL, Ali R, Connolly ID, Henderson JM, et al
    Awake versus asleep deep brain stimulation for Parkinson's disease: a critical comparison and meta-analysis.
    J Neurol Neurosurg Psychiatry. 2017 Mar 1. pii: jnnp-2016-314500.
    PubMed     Text format     Abstract available

  7. LAWSON RA, Yarnall AJ, Duncan GW, Breen DP, et al
    Stability of mild cognitive impairment in newly diagnosed Parkinson's disease.
    J Neurol Neurosurg Psychiatry. 2017 Mar 1. pii: jnnp-2016-315099.
    PubMed     Text format     Abstract available


    Mov Disord

  8. GIANNOCCARO MP, La Morgia C, Rizzo G, Carelli V, et al
    Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease.
    Mov Disord. 2017 Mar 2. doi: 10.1002/mds.26966.
    PubMed     Text format     Abstract available


  9. Abstracts of the 1st Pan American Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2017;32 Suppl 1:S1-S90.
    PubMed     Text format    

  10. ESPAY AJ, Schwarzschild MA, Tanner CM, Fernandez HH, et al
    Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
    Mov Disord. 2017 Feb 24. doi: 10.1002/mds.26913.
    PubMed     Text format     Abstract available


    Nervenarzt

  11. WITT K, Kalbe E, Erasmi R, Ebersbach G, et al
    [Nonpharmacological treatment procedures for Parkinson's disease].
    Nervenarzt. 2017 Mar 1. doi: 10.1007/s00115-017-0298.
    PubMed     Text format     Abstract available


    Neurochem Res

  12. YUE P, Gao L, Wang X, Ding X, et al
    Intranasal Administration of GDNF Protects Against Neural Apoptosis in a Rat Model of Parkinson's Disease Through PI3K/Akt/GSK3beta Pathway.
    Neurochem Res. 2017 Feb 28. doi: 10.1007/s11064-017-2184.
    PubMed     Text format     Abstract available

  13. MAO Z, Liu C, Ji S, Yang Q, et al
    The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson's Disease in Rats.
    Neurochem Res. 2017 Feb 28. doi: 10.1007/s11064-017-2185.
    PubMed     Text format     Abstract available


    Neurol Clin Pract

  14. ESPAY AJ, Pagan FL, Walter BL, Morgan JC, et al
    Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.
    Neurol Clin Pract. 2017;7:86-93.
    PubMed     Text format     Abstract available


    Neurology

  15. BUCHMAN AS, Bennett DA
    Author response: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:920.
    PubMed     Text format    

  16. BOHNEN NI, Muller M
    Letter re: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:920.
    PubMed     Text format    

  17. BUCHMAN AS, Bennett DA
    Author response: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:919-920.
    PubMed     Text format    

  18. MAHLKNECHT P, Kiechl S, Willeit J, Poewe W, et al
    Letter re: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:919.
    PubMed     Text format    

  19. GOLDMAN JG, Bledsoe IO, Merkitch D, Dinh V, et al
    Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003764.
    PubMed     Text format     Abstract available


    Neurosci Lett

  20. TANG Y, Meng L, Wan CM, Liu ZH, et al
    Identifying the presence of Parkinson's disease using low-frequency fluctuations in BOLD signals.
    Neurosci Lett. 2017 Feb 26. pii: S0304-3940(17)30172.
    PubMed     Text format     Abstract available


    PLoS One

  21. NACKAERTS E, Heremans E, Smits-Engelsman BC, Broeder S, et al
    Validity and reliability of a new tool to evaluate handwriting difficulties in Parkinson's disease.
    PLoS One. 2017;12:e0173157.
    PubMed     Text format     Abstract available

  22. LU J, Li X, Wang Q, Pei G, et al
    Dopamine D2 receptor and beta-arrestin 2 mediate Amyloid-beta elevation induced by anti-parkinson's disease drugs, levodopa and piribedil, in neuronal cells.
    PLoS One. 2017;12:e0173240.
    PubMed     Text format     Abstract available

  23. WESTPHAL R, Simmons C, Mesquita MB, Wood TC, et al
    Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson's disease.
    PLoS One. 2017;12:e0172394.
    PubMed     Text format     Abstract available

  24. KRUSE N, Schlossmacher MG, Schulz-Schaeffer WJ, Vanmechelen E, et al
    A First Tetraplex Assay for the Simultaneous Quantification of Total alpha-Synuclein, Tau, beta-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
    PLoS One. 2016;11:e0153564.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  25. DUNN AR, Stout KA, Ozawa M, Lohr KM, et al
    Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease.
    Proc Natl Acad Sci U S A. 2017 Feb 28. pii: 201616892.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: